Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance
Open Access
- 1 January 2017
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 23 (18) , 3367-3373
Abstract
To evaluate the efficacy of antimicrobial susceptibility-guided therapy before first-line treatment for infection in patients with dual or triple antibiotic resistance. A total of 1034 patients infected by Helicobacter pylori (H. pylori) during 2013-2014 were tested for antimicrobial susceptibility. 157 of 1034 (15%) patients showed resistance to two (127/1034; 12%) and to three (30/1034; 3%) antibiotics. Sixty-eight patients with dual H. pylori-resistance (clarithromycin, metronidazole or levofloxacin) were treated for 10 d with triple therapies: OAL (omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and levofloxacin 500 mg b.i.d.) 43 cases, OAM (omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg b.i.d.) 12 cases and OAC (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d.) 13 cases based on the antimicrobial susceptibility testing. Twelve patients showed triple H. pylori-resistance (clarithromycin, metronidazole and levofloxacin) and received for 10 d triple therapy with OAR (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d.). Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. Intention-to-treat eradication rates were: OAL (97.6%), OAM (91.6%), OAC (92.3%) and OAR (58.3%). Cure rate was significantly higher in naïve patients treated with OAR-10 compared to patients who had two or three previous treatment failures (83% vs 33%). Adverse events rates for OAL, OAM, OAC and OAR were 22%, 25%, 23% and 17%, respectively, all of them mild-moderate. Antimicrobial susceptibility-guided triple therapies during 10 d for first-line treatment leads to an eradication rate superior to 90% in patients with dual antibiotic H. pylori resistance.Keywords
This publication has 19 references indexed in Scilit:
- Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus ReportGut, 2016
- Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics, 2015
- Optimizing clarithromycin-containing therapy forHelicobacter pyloriin the era of antibiotic resistanceWorld Journal of Gastroenterology, 2014
- The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapyTherapeutic Advances in Gastroenterology, 2012
- Review article: rifabutin in the treatment of refractoryHelicobacter pyloriinfectionAlimentary Pharmacology & Therapeutics, 2011
- The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practiceAlimentary Pharmacology & Therapeutics, 2007
- Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 2007
- Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from GermanyJournal of Antimicrobial Chemotherapy, 2007
- Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: a Prospective, Randomized, Multicenter, North American TrialAmerican Journal of Gastroenterology, 2003
- How Long for the Routine Helicobacter pylori Antimicrobial Susceptibility Testing? The Usefulness of the String Test to Obtain Helicobacter for CultureAmerican Journal of Gastroenterology, 1999